Since it was first reported in 2013 that APE1/Ref-1 secretion is increased by intracellular hyperacetylation [4], it has subsequently been reported that its secretion is increased in lipopolysaccharide-induced endotoxemic animal models [5], apolipoprotein E-deficient mice fed Western-type diets [1], and patients with coronary artery disease [6], suggesting its usefulness as a new biomarker for vascular inflammation. Here, APEX1 is linked to coronary artery disorder.